Login to Your Account

Earnings Roundup

Isis Peers Beyond Kynamro, Seeks $171M for Pipeline

By Marie Powers
Staff Writer

Friday, May 10, 2013
Hours after reporting its first quarterly earnings as a commercial entity following FDA approval of Kynamro (mipomersen) in January and subsequent launch of the antisense drug, Isis Pharmaceuticals Inc. turned its attention to other candidates in its pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription